Compare AbbVie Inc (ABBV) vs Dow Inc (DOW) Price & Performance

AbbVie (ABBV) trades at $247.91, up 0.76% on the day, with strong technical momentum as the stock approaches resistance near $249. The company demonstrates solid fundamentals with Q2 2026 EPS beating expectations at $3.65 versus $3.61, driven by robust immunology portfolio growth from Skyrizi and Rinvoq offsetting Humira declines. Revenue reached $61.16B in 2025 with a 71.48% gross margin, though net income margin compressed to 9.8%. Recent positive Phase 2 ovarian cancer data and institutional accumulation signal confidence in the pipeline.

Outlook remains positive with analyst consensus target of $281.33 (13.5% upside) and 71% buy ratings, though elevated P/E of 70.05 reflects growth expectations. Key risks include patent cliffs in the 2030s, competitive pressures, and regulatory uncertainties from drug pricing lawsuits. The dividend aristocrat offers income stability with recent $1.73 payout, but investors should monitor execution of oncology pipeline and debt levels at 50.4% of assets.

DOW trades at $29.34, down 3.17% today, with technical indicators showing bearish momentum. The company faces fundamental challenges with negative net income margin of -3.13% and declining revenue from $56.9B in 2022 to $40.0B in 2025. Recent earnings beats provide some optimism, but cash flow from operations has weakened significantly from $7.5B in 2022 to $1.0B in 2025. The stock trades near the lower end of analyst price targets with consensus at $35.11.

DOW presents a mixed investment case with valuation metrics showing potential undervaluation (P/S 0.51) offset by profitability concerns. The chemical sector faces cyclical pressures, but recent dividend payments and earnings beats suggest operational resilience. Key risks include continued revenue decline and high debt levels approaching 30% of assets. Analyst sentiment remains cautious with only 33% buy ratings.